Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · SpyGlass Pharma, Inc. (SGP)

SpyGlass Pharma buys IOL maker Advanced Vision Science for $13 million

Neutral Impact 3 of 5 m&a Written later

SpyGlass Pharma closed its purchase of 100% of Advanced Vision Science, Inc. (AVS) on October 1, 2026, from Santen Holdings US, Inc. AVS had been SpyGlass Pharma's intraocular lens (IOL) supplier, and the company says the deal secures its IOL manufacturing supply for its Phase 3 BIM-IOL System.

Key points

  • Purchase price was $13,000,000, subject to customary adjustments, including a post-Closing adjustment
  • Closing occurred on October 1, 2026; Santen Pharmaceutical Co., Ltd. guaranteed the seller's obligations under the Purchase Agreement
  • AVS will continue to manufacture and supply Eternity brand IOLs to Santen, which has an exclusive right to sell them in Japan
  • AVS and Santen entered into cross license agreements allowing both parties to continue operating their businesses

The filing

CompanySpyGlass Pharma, Inc. (SGP)
Form8-K, current report
Filed with the SECOct 1, 2026, 8:15 AM ET
Accession number0001778922-26-000049

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 01, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.